Phenome-wide association study of ovarian cancer identifies common comorbidities and reveals shared genetics with complex diseases and biomarkers

Anwar Mulugeta^{1,2&3*}, Amanda L Lumsden^{1&2}, Iqbal Madakkatel^{1&2}, David Stacey^{1&2}, S.Hong Lee^{1,2&4}, Johanna Mäenpää^{5&6}, Martin K. Oehler^{7&8}, Elina Hyppönen^{1&2}

Short title: MR-PheWAS of ovarian cancer

Funding: This research was funded by Medical Research Future Fund of Australia (MRF2007431).

Competing interests: The authors declare that they have no competing interests.

*Corresponding author:

Dr Anwar Mulugeta

Australian Centre for Precision Health, c/o SAHMRI, University of South Australia, Adelaide, Australia, GPO Box 2471, Adelaide SA 5001.

Email: anwarmulugeta.gebremichael@unisa.edu.au

¹Australian Centre for Precision Health, Unit of Clinical and Health Sciences, University of South Australia, Adelaide, Australia

²South Australian Health and Medical Research Institute, Adelaide, Australia

³Department of Pharmacology and Clinical Pharmacy, College of Health Science, Addis Ababa University, Addis Ababa, Ethiopia

⁴UniSA Allied Health & Human Performance, University of South Australia, Adelaide, SA, Australia

⁵Faculty of Medicine and Medical Technology, Tampere University, Tampere, Finland

⁶Cancer Centre, Tampere University and University Hospital, Tampere, Finland

⁷Department of Gynaecological Oncology, Royal Adelaide Hospital, Adelaide, SA, Australia

⁸Adelaide Medical School, Robinson Research Institute, University of Adelaide, Adelaide, SA, Australia

Abstract

1

- 2 Background: Ovarian cancer (OC) is commonly diagnosed among older women who have
- 3 comorbidities. This hypothesis-free phenome-wide association study (PheWAS) aimed to identify
- 4 comorbidities associated with OC, as well as traits that share a genetic architecture with OC.
- 5 Methods: We used data from 181,203 white British female UK Biobank participants and analysed
- 6 OC and OC subtype-specific genetic risk scores (OC-GRS) for an association with 889 diseases and
- 7 43 other traits. We conducted PheWAS and colocalisation analyses for individual variants to identify
- 8 evidence for shared genetic architecture.
- 9 Results: The OC-GRS was associated with 10 diseases, and the clear cell OC-GRS was associated
- with five diseases at the FDR threshold (p = 5.6×10^{-4}). Mendelian randomisaiton analysis (MR)
- 11 provided robust evidence for the association of OC with higher risk of "secondary malignant
- 12 neoplasm of digestive systems" (OR 1.64, 95% CI 1.33, 2.02), "ascites" (1.48, 95% CI 1.17, 1.86),
- 13 "chronic airway obstruction" (1.17, 95% CI 1.07, 1.29), and "abnormal findings on examination of
- 14 the lung" (1.51, 95% CI 1.22, 1.87). Analyses of lung spirometry measures provided further support
- 15 for compromised respiratory function. PheWAS on individual OC variants identified five genetic
- variants associated with other diseases, and seven variants associated with biomarkers (all, p \leq 4.5×10
- 17 8). Colocalisation analysis identified rs4449583 as the shared causal variant for OC and seborrheic
- 18 keratosis.
- 19 Conclusions: OC is associated with digestive and respiratory comorbidities. Several variants
- affecting OC risk were associated with other diseases and biomarkers, with this study identifying a
- 21 novel genetic locus shared between OC and skin conditions.

22

Keywords: Ovarian cancer, comorbidities, *TERT*, PheWAS, UK Biobank

1. Introduction

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

Ovarian cancer (OC) is a notorious gynaecological disorder, with only 44% of affected women surviving 5 years. Reducing mortality associated with OC remains a challenge as the poor understanding of the origin and biology of the disease limits opportunities to prevention, and the disease is typically detected at an advanced stage when treatment options are limited.² Approximately 90% of OC are epithelial OC and arise from epithelial cells, predominantly of the fallopian tube and endometrium.²⁻⁴ Epithelial OC can be further classified into serous, endometroid, clear cell, and mucinous subtypes, based on their histological characteristics³ and indeed, the pathogenesis, disease progression, and risk factors are known to vary between OC subtypes.^{3,5} Given that OC is commonly diagnosed in women aged 50 years and above, many patients present with at least one comorbidity, which can influence treatment decisions, impact prognosis and affect overall survival.^{7,8} Hence, exploring the associations between OC and comorbidities, along with understanding potential shared genetic links between OC and other traits, may offer insights into the underlying etiology of the disease. Such insights could lead to facilitating earlier detection and better management of the disease. Phenome-wide association study (PheWAS) is a powerful approach for testing the association of genetic variants or their risk score with a broad range of phenotypes and disease outcomes.⁹ This approach offers the advantage of being hypothesis-free, allowing it to explore numerous associations without constraints of the number of outcomes. Consequently, PheWAS has the potential to unveil novel genetic associations with diseases. In this study we use data on genetic OC risk variants and 889 disease outcomes from 181,203 female UK Biobank participants to identify comorbidities and clinical characteristics associated with the genetic risk of OC. We test for evidence of a direct association between OC and possible comorbidities using Mendelian randomisation (MR), an approach less susceptible to confounding and reverse causation, 10 and extend these analyses to focus on the genetic risk reflecting distinct histological OC subtypes. We also use the PheWAS approach to explore each OC associated variant individually, which can provide evidence for shared genetic contributions, and provide insight into the underlying disease mechanisms.

2. Methods

2.1. Study population

UK Biobank is a prospective cohort study of half a million participants with rich phenotype and genotype data collected across 22 centres in England, Scotland, and Wales. The baseline assessment was conducted between 2006 and 2010 when the participants were aged between 37 to 73 years. A wide range of data was collected, including sociodemographic information, lifestyle factors, physical measures, blood and urine samples for biomarker and genetic profiling, with continuing updates through follow-up assessments and linkage with electronic health records and death registrations. For the primary analyses in this study, we restricted the sample to 181,203 female participants who were of white British ancestry and were not genetically related (Figure S1) and included male participants in sensitivity analyses (n =156,220). The study was conducted under UK Biobank application number 89630. UK Biobank obtained informed consent from all participants to collect and use linked data for future research use, and the UK Biobank study has ethical approval from the National Information Governance Board for Health and Social Care and Northwest Multicenter Research Ethics Committee (11/NW/0382).

2.2. Disease outcomes and biomarkers

We used International Classification of Diseases (ICD version 9 and 10) codes from hospital episode statistics and death registrations to identify disease outcomes (Supplementary methods). We mapped ICD-9/10 codes to phecodes, which are composite groupings reflecting clinically relevant disease outcomes. We defined individuals with the phecode-of-interest as cases, and those without the phecode-of-interest, or any other phecodes from the same disease category as controls (Supplementary methods). We included all phecodes with at least 200 cases in our analyses, resulting in 889 phecodes from 18 disease categories (Table S1).

We also included 30 serum and four urine biomarkers, which are commonly used for the diagnosis and monitoring of chronic diseases, as outcome measures (Supplementary methods). Additional analyses were conducted against selected physiological characteristics (namely body mass index (BMI), body fat percentage (BFP), basal metabolic rate (BMR), blood pressures, and measures of lung function (spirometry) due to their known associations with comorbidity risks. The spirometry measures included forced expiratory volume in 1-second (FEV1), forced vital capacity (FVC), FEV1/FVC ratio, and peak expiratory flow (PEF). 2.3. Genetic variants and genetic risk score We selected 35 genetic variants associated with OC from previous genome-wide association studies (GWAS), including the 12 novel variants identified in the most recent GWAS ¹⁵ and 23 variants identified in earlier GWASs (minor allele frequency >1.4%, Table S2, Figure S2). 16-23 We constructed the genetic risk score (GRS) using 31 genetic variants after excluding one variant that had no proxy at $r^2 \ge 0.8$ (rs555025179), and three variants (rs12131772, rs4691139, and rs12938171) that were not replicated in the recent GWAS, 15 which we extracted from the imputed genotype UK Biobank data ²⁴ (Table S2). The GRS was constructed for each individual by summing the weighted number of OC risk-associated variants, with the weight taken from the recent OC GWAS. 15 We also constructed risk scores for each OC subtype (Supplementary methods). 2.4. Statistical analyses We conducted phenome-wide analyses using R-package PheWAS ²⁵ which allowed us to fit logistic regression (889 disease outcomes) or linear regression (43 biomarkers/physiological characteristics) against the OC GRS with all models adjusted for age, assessment centre, type of genotyping array, birth location, and 40 principal components (Figure S2). We repeated the phenome-wide analyses for

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

specific mechanistic pathways.

5

each OC subtype GRS to identify subtype-specific disease associations, and further, conducted the

analyses in male participants to understand whether the OC – disease associations involve non-sex-

The phenome-wide association signals that passed the FDR threshold (p $< 5.6 \times 10^{-4}$ for the diseases and p < 0.02 for the biomarkers and physiological measures, Supplementary methods) were taken forward to MR analysis to examine evidence for direct association with OC. We used two-sample MR approach where variant – OC association estimates were taken from the recent OC GWAS, 15 and the variant-outcome association estimates were from the UK Biobank. MR analyses were conducted on signals associated with the overall OC GRS or with any subtype-based GRSs. We used inverse variance weighted (IVW) MR²⁶ as the primary method and conducted sensitivity analyses using weighted median,²⁷ weighted mode,²⁸ MR-PRESSO,²⁹ and MR-Egger,³⁰ with each method working on different pleiotropic assumptions (Supplementary methods). We tested for horizontal pleiotropy using MR-Egger intercept, MR-PRESSO outlier and distortion tests, leave-one-out and leave-block-out methods (Table S3, Supplementary methods). MR analyses were repeated excluding the OC cases. To test the MR assumption that the genetic instrument should not be associated with potential confounding factors, we explored the association between the OC GRSs and age, education, Townsend deprivation index, BMI, physical activity, and alcohol consumption (Supplementary methods, Table S4). We repeated the phenome-wide analyses for each OC genetic variant individually, again conducting analyses separately for men. We assessed the novelty of the PheWAS findings by checking the reported associations in the GWAS Catalog. We considered a locus-trait association as potentially novel if neither the lead variant nor any variant in linkage disequilibrium (LD) with the lead variant (with an $r^2 \ge 0.1$) had previously been reported to be associated with the same or related traits. For those potentially novel associations, we conducted a follow-up colocalisation analysis using the HyPrColoc (Hypothesis Prioritization in multi-trait Colocalisation) tool to assess whether there is evidence of shared causal genetic variants between pairs of traits.³¹ We considered a posterior probability of full colocalisation (PPFC) >0.64 as indicative of shared genetic etiology between these traits (Supplementary methods).³¹ Statistical analyses were performed using STATA SE version 17.1, R version 4.2.1 and PLINK2.³²

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

3. Results

We included up to 181,203 female white British participants in the primary analyses, of whom 1,863 (1.3%) had been diagnosed with OC (Table 1). The prevalence of OC was higher among participants who were older, obese, never drinkers of alcohol, and those with poor general health status at the baseline (for all, prevalence \geq 1.2%, and p \leq 0.03). The OC risk GRS was normally distributed and associated with OC as expected, with stronger association in the highest compared to the lowest genetic risk group (F-statistics =23.7, p =4.4 \times 10⁻¹⁶, Figure S3). No associations were found between the risk scores and potential confounders after correction for multiple testing (Table S5).

3.1. Phenome-wide-based Mendelian randomisation

We investigated 889 disease outcomes from 18 disease categories in the phenome-wide analyses. We observed significant associations between the OC GRS and 10 diseases from four disease categories (neoplasms, digestive, respiratory and genitourinary diseases) after FDR correction ($p \le 5.6 \times 10^{-4}$). The top signals were for "cancer of the female genital organs", "malignant neoplasm of ovary and other uterine adnexa", and "malignant neoplasm of the ovary", which confirms the 'relevance assumption' of the MR approach¹⁰ (Supplementary methods) for using the GRS as instrument for OC (for all, $p \le 4.8 \times 10^{-4}$, Figure 1, Panel A). The GRS was also associated with higher risk of other cancers and abnormal growths including "secondary malignant neoplasm of digestive systems", "lipoma, including lipoma of skin and subcutaneous tissue" ($p \le 3.9 \times 10^{-4}$), and "ovarian cyst" ($p = 6.0 \times 10^{-5}$). In addition, we identified associations with respiratory outcomes including "chronic airway obstruction" and "abnormal findings on examination of the lungs", and with the digestive system outcome, "ascites" ($p \le 3.2 \times 10^{-4}$).

In analyses using GRSs for specific OC subtypes (Figure 1 Panel B and C), the clear cell OC GRS was associated with additional diseases and increased risks such as "benign neoplasm of uterus", and "uterine leiomyoma", "disorders of menstruation", "gram negative septicemia", and "postoperative infection" (for all, $p \le 2.3 \times 10^{-4}$). Overall, in addition to overall OC-related outcomes, 12 other disease outcomes were associated with at least one form of the OC GRS. Notably, none of these associations were detected when we repeated the phenome-wide analyses among men (Figure S4).

154 Additionally, our phenome-wide analyses on 43 quantitative traits, which included serum and urine 155 biomarkers and physiological measures, identified an association of OC GRS with 13 traits. 156 Furthermore, we found an additional 11 traits associated with at least one subtype of OC GRS (Figure 157 S5). 158 We conducted two-sample MR analyses on 12 disease outcomes identified in the PheWAS. For each 159 outcome, evidence of causality was identified for at least one type of OC (Figure 2). We found robust 160 evidence supporting the association between a higher genetic liability of OC and an increased risk of 161 "secondary malignant neoplasm of digestive systems" (OR 1.64, 95% CI 1.33, 2.023), "ascites" (1.48, 162 95% CI 1.17, 1.86), "chronic airway obstruction" (1.17, 95% CI 1.07, 1.29), and "abnormal finding 163 on the examination of the lungs" (1.51, 95% CI 1.22, 1.87). These associations were further supported 164 by other MR methods (Figure S6). Additionally, we observed an association between a higher genetic 165 liability of OC and an increased risk of "ovarian cyst" (1.23, 95% CI 1.04, 1.46), as well as "lipoma 166 including lipoma of skin and subcutaneous tissues" (1.31, 95% CI 1.06, 1.61). Notably, the weighted 167 median and weighted mode MR methods specifically supported the association with "lipoma of the 168 skin and subcutaneous tissues" (Figure S6). There was some evidence supporting the association 169 between OC and higher risk of "postoperative infection" and "gram-negative septicemia", identified 170 in the phenome-wide analyses on clear cell OC. However, these associations were observed only in 171 the IVW and MR-PRESSO MR methods (Figure S6). In the MR analyses on OC subtypes (Figure 2), 172 serous, endometrioid and clear cell OC were all associated with "secondary malignant neoplasm of 173 digestive systems" and "ascites". Serous and endometrioid subtypes showed evidence of effects on 174 the respiratory outcomes. While the case numbers were lower for mucinous OC, this histotype was the 175 only one to show evidence of an association with "lipoma of the skin and subcutaneous tissues" as 176 evidenced by all MR methods. However, mucinous OC was not associated with any of the other 177 outcomes (Figure S6). The clear cell subtype was associated with "ovarian cyst", "benign uterine 178 neoplasms", "uterine leiomyoma", and "disorders of menstruation". Both serous and clear cell 179 subtypes increased the risk of postoperative infection traits, with clear cell also increasing risk for 180 "gram negative septicemia" (Figure 2 & Figure S6). We conducted analyses also excluding all known

OC cases, and associations with "secondary malignant neoplasm of digestive systems" and "ascites" were attenuated, while estimates for all other outcomes were generally similar to the main findings (Figure S7). The MR-Egger intercept did not suggest evidence of pleiotropy for most associations, except for the association between serous OC and "postoperative infections" (p_{intercept} =0.01), which therefore should be cautiously interpreted. No evidence of pleiotropy was found using the MR-PRESSO outlier test and leave-one-out analysis (Figure S8). The estimates obtained from leave-block-out analyses were broadly consistent with the overall findings (Figure S9).

MR analyses on serum biomarkers and physiological measures supported the association of OC with lower FVC, endometrioid OC with lower oestradiol, clear cell OC with lower total cholesterol, low density lipoprotein (LDL) cholesterol, and apolipoprotein B (ApoB), and mucinous OC with higher gamma glutamyltransferase (GGT) and alanine aminotransferase (ALT) and lower creatinine levels (Figure S10). Analyses excluding all known OC cases, provided generally similar estimates to the main findings (Figure S11). For these identified associations, we did not find any evidence of pleiotropy based on the MR-Egger intercept tests ($p_{intercept} \ge 0.13$) and leave-one-out analyses. MR analyses on men provided evidence for a genetic association between mucinous OC and ALT (Figure S10).

3.2. Shared genetic architecture

In the phenome-wide analyses assessing associations with individua OC risk-associated genetic variant, five variants were associated with at least one of 15 (11 distinct) disease outcomes (all, p \leq 4.5 \times 10⁻⁸, Figure 3, Table S6), and seven variants were associated with at least one of 22 biomarkers and physiological measures (Figure S12). Some of these associations were also observed in the analyses among men, with selected OC variants affecting conditions of the male genital organs (Figure 3, Table S6 and Figure S12, Supplementary Results). To ensure the novelty of our findings, we extensively checked the GWAS Catalog for any reports of associations with the identified (or related) diseases involving the lead or proxy variants ($r^2 \geq$ 0.1). As a result, we uncovered potential novel associations between the OC risk-increasing allele from the *TERT* locus (rs10069690-T) and a lower

risk of "seborrheic keratosis" (0.79, 95% CI 0.72, 0.87), in females, with similar a finding observed in males. To further validate the associations, we conducted colocalisation analysis at the *TERT* locus (LD block of chr5:982252 to chr5:2132442, human genomic build of hg19) and identified rs4449583 as the candidate causal variant explaining around 70% of 0.9239 PPFC for OC-"seborrheic keratosis" (Figure 4). This variant is also strongly associated with OC in the Phelan OC GWAS¹⁵ (p =7.8 ×10⁻¹²), and in LD with the index variant from this GWAS (rs7705526, r^2 = 0.784) and with the lead variant in the primary discovery OC GWAS²² (rs100699690, r^2 =0.432, Supplementary Methods). The association between the *GPX6* locus and "disorders of iron metabolism" and "celiac disease" are potentially novel, although colocalisation analysis did not suggest that OC share the same causal variants with these two diseases (Figure S13). On the contrary, we identified independent potential causal genetic variant for each "disorders of iron metabolism" (rs34409925, r^2 = 0.207 with rs6456822) and "celiac disease" (rs3131101, r^2 =0.049 with rs6456822) in further conditional analysis (Figure S13).

4. Discussion

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

In this large-scale phenome-wide study, we aimed to explore comorbidity risks associated with OC, with additional analyses to identify subtype-specific associations based on genetic variants reflecting different OC histological types. We found evidence supporting a possible causal association between OC and 12 disease outcomes, including "secondary malignant neoplasm of the digestive system", "ascites", and respiratory disorders. We also identified some additional subtype-specific associations, including clear cell OC showing links with "gram-negative septicemia", "uterine leiomyoma" and "disorders of menstruation", and mucinous OC with "lipoma of the skin and subcutaneous tissue". Analyses using 43 biomarkers also identified an association with seven biomarkers and these findings, along with those from disease analyses, may have important implications for improving the clinical management of patients with OC. Moreover, our exploration of each OC-risk increasing variant in the PheWAS revealed a set of traits that are genetically shared with OC. This analysis not only confirmed previous GWAS findings but also shed light on novel associations deserving further investigations. OC is the leading cause of cancer-related ascites in females.³³ Our MR-PheWAS study revealed genetic evidence linking ascites to OC across all subtypes except mucinous OC, which is consistent with the fact that over one-third of women with OC develop ascites during their lifetime. 33, 34 Ascites is commonly considered a sign of advanced OC, 35 and in line with this, the evidence for an association in our analyses was removed after excluding known OC cases. In patients with OC, the presence of ascites commonly indicates metastasis to peritoneal surfaces and reflects the extent of the disease.³⁶ Our study further established a causal association between OC and "secondary malignant neoplasms of the digestive system", indicating intra-abdominal dissemination of the tumour. Again, this association was sensitive to the inclusion of known OC cases in our analyses, and is likely to explained by a metastasis of the OC affecting the gastrointestinal tract or, potentially, a new synchronous gastrointestinal cancer. OC has also been linked to respiratory complications. ^{37, 38} Our study provides additional supporting evidence for this association, specifically linking OC to an increased risk of "chronic airway

obstruction" and "abnormal lung examinations". The findings were further supported by spirometry measures, which showed a significant association between a higher genetic liability to OC and lower FVC. While in women with OC lowering of lung function may follow from malignant pleural effusion and tumour metastasis to the pleura³⁷ or complications related to surgical procedures,³⁸ in our analysis the association with lung disease remained when OC cases were excluded, and the spirometric association was seen both in women and in men, which may indicate a more profound biological link. OC as reflected by our genetic study arises from the epithelium of the ovaries, endometrium and fallopian tubes, and while most of the lung also consists of epithelium, a direct link has not been well established. Interestingly, colocalisation analyses in our study also suggested that disorder of skin condition (seborrheic keratosis) shared a genetic locus (TERT, encoding the enzyme, telomerase) with OC, highlighting potential shared pathomechanisms involving the epithelium, and implicating telomerase function in the opposing risks of OC and the skin disorder.^{39, 40} Debulking cytoreductive surgery is the standard procedure for advanced OC. It involves the surgical removal of female reproductive organs such as the ovaries, fallopian tubes, uterus, as well as omentum and organs of the digestive system, such as the bowel, depending on the stage of OC. 41 The invasive nature of this intervention. 41 combined with compromised immune system function resulting from the disease, ⁴² may explain the observed association between OC and "postoperative infection" and "gram-negative septicemia". It is important to note that these associations were predominantly observed in clear cell OC, which has also been associated with "benign neoplasms of the uterus", "uterine leiomyoma", and "disorders of menstruation". The presence of these conditions, which primarily involve the uterine tissue, could reflect the well-established association between endometriosis and clear cell OC. 43, 44 Our study also identified OC subtype specific associations between mucinous OC and "lipoma of the skin and subcutaneous tissue". Regarding the biomarkers, endometroid OC was associated with lower serum oestradiol level, clear cell OC was associated with lower serum total cholesterol, LDL cholesterol, and ApoB, while mucinous OC was associated with higher serum GGT and ALT as well as lower creatinine levels. These findings suggests that

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

275 subtypes of OC. 276 Beyond the causal link between OC and disease outcomes and biomarkers, genetic variants 277 contributing to a higher risk of OC may also be associated with other diseases and biomarkers. The 278 ABO locus is a well-known pleiotropic locus with established associations with cardiovascular and cerebrovascular traits. 45-50 Our study confirmed these existing findings, as we also observed 279 280 associations between the ABO variant and conditions such as "pulmonary heart disease", 281 "thrombophlebitis", and "other disorders of circulatory system". Additionally, we confirmed the 282 association between ABO with many cardiometabolic biomarkers, including associations with markers of glucose and liver metabolism, confirming the highly pleiotropic nature of this variant.⁵¹ 283 284 Our study identified a significant association between the GPX6 variant (rs6456822) and a lower risk 285 of disorders related to iron metabolism, which is a critical component of overall health.⁵² However, 286 while the lead variant rs6456822 showed this association, our colocalisation analysis identified an 287 independent potential causal variant, rs34409925, for "disorders of iron metabolism". We also found 288 another potential causal variant at the GPX6 locus, rs3131101, for "celiac disease". The OC lead 289 variant rs6456822 was also associated with total protein levels in women, as well as with SHBG 290 levels in men. Our study also identified a potential novel association between the TERT locus 291 (rs10069690) and "seborrheic keratosis". The follow up colocalisation analysis strengthened the 292 shared genetic structures between this skin condition and OC, further suggesting that rs444583 may 293 be a causal variant. Importantly, we confirmed previous associations of the TERT variant with uterine leiomyoma^{44, 53} and total protein levels in women^{49, 51}, as well as with prostate cancer in men.⁵⁴ Our 294 295 findings highlight the value of using PheWAS for validating previous GWAS findings and identifying 296 potential novel variants for multiple traits including diseases and biomarkers that never been tested 297 before.55 298 Our study has a number of strengths. Firstly, it is the largest (n = 181,203) and most comprehensive 299 study to date that examines the health risks associated with a higher genetic susceptibility to OC.

comorbidities and selected biomarkers may play a role in identifying and characterising different

Secondly, by including OC subtypes in our analysis, our study can identify subtype-specific comorbidities, supporting more effective treatment and management. Lastly, our study extended the phenome-wide analyses to each OC-risk-increasing variant. This approach enables us to confirm previously identified variant-disease associations and also identify potential novel associations, thus providing a more comprehensive understanding of the shared genetic links between OC and other diseases. Further incorporation of colocalisation analysis is another strength of this study. It provided evidence of a shared genetic locus (TERT) between OC and "seborrheic keratosis", and identified a potential novel causal variant, rs4449583, for this skin condition. Our study also has some limitations. To ensure the validity of MR, the genetic instrument used must be associated with the risk factor (in our case, OC), not associated with the confounders of the risk factor-outcome association, and not influence the outcome except through its association with the risk factor. While we used a genetic instrument that associates with OC and conducted our analysis on a white-European population while adjusting for confounding factors, we cannot rule out the absence of horizontal pleiotropic effects, which will affect interpretation and can bias the MR estimates. 56 To address this concern, we repeated our analysis in men to further verify whether the association we observed is genuinely related to OC or a reflection of genetic variants indicating shared mechanistic pathways between both men and women. Another potential limitation of our study is that the UK Biobank participants are relatively healthy compared to the general population, ⁵⁷ introducing to collider bias due to the "healthy volunteer" selection bias. 58 However, the modest collider bias in the context of MR is less likely to affect MR results significantly when the selection into the study was not strongly influenced by the risk factor. 58 Furthermore, the presence of biologically plausible causal associations in our study provides support for the validity of our results despite this limitation. It could be noted as a limitation of our study that our investigation into comorbidities associated with OC was primarily conducted in a population predominantly not diagnosed with OC. However, sensitivity analyses excluding all known OC cases confirmed that the associations with OC complications relating to ascites and gastrointestinal metastases are related to the disease per se, while the other

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

observed disease and trait associations may reflect earlier stages of OC development or other underlying biological differences.

In conclusion, our study identified robust associations between OC and comorbidities related to the digestive and respiratory systems. Furthermore, we observed specific robust associations for different subtypes of OC, such as "gram-negative septicemia", 'uterine leiomyoma" and "disorders of menstruation" for clear cell OC, and lipoma for mucinous OC. Interestingly, our study points to a shared genetic architecture between OC and a skin condition, leading to a discovery of a novel variant which merits further investigation.

333	Funding
336	This study was supported by Medical Research Future Fund of Australia (MRFF), grant number
337	2007431.
338	
339	Competing interests
340	The authors declare that they have no competing interests.
341	
342	Acknowledgements
343	The authors are very grateful to the UK Biobank and UK Biobank Participants.
344	
345	Authors' contributions
346	AM conceived the study with EH, conducted the analysis, and wrote the first draft. E.H. supervised
347	the study and advised on analyses. DS conducted the colocalisation analysis using summary results
348	generated by AM. All authors interpreted the results, revised the manuscript, and approved the final
349	manuscript.
350	
351	Ethical approval
352	The study was conducted under UK Biobank application number 89630. UK Biobank study has
353	ethical approval from the National Information Governance Board for Health and Social Care and
354	Northwest Multicenter Research Ethics Committee (11/NW/0382).
355	Consent to participate
356	UK Biobank obtained informed consent from all participants to collect and use linked data for future
357	research use.

Data availability359 This research has been conducted using the UK Biobank Resource under Application Number 89630. 360 The data and analytical code that support the findings of this study are available on application to the 361 UK Biobank (https://www.ukbiobank.ac.uk/enable-your-research/apply-for-access). 362

References

- 1. DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, Alteri R, Robbins AS, Jemal A. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin 2014;64:252-71.
 - 2. Kurman RJ, Shih Ie M. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol 2010;34:433-43.
 - 3. Sankaranarayanan R, Ferlay J. Worldwide burden of gynaecological cancer: the size of the problem. Best practice & research. Clinical obstetrics & gynaecology 2006;20:207-25.
 - 4. Perets R, Wyant GA, Muto KW, Bijron JG, Poole BB, Chin KT, Chen JY, Ohman AW, Stepule CD, Kwak S, Karst AM, Hirsch MS, et al. Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca;Tp53;Pten models. Cancer Cell 2013;24:751-65.
 - 5. Lheureux S, Gourley C, Vergote I, Oza AM. Epithelial ovarian cancer. The Lancet 2019;393:1240-53.
 - 6. Zhang S, Cheng C, Lin Z, Xiao L, Su X, Zheng L, Mu Y, Liao M, Ouyang R, Li W, Ma J, Cai J, et al. The global burden and associated factors of ovarian cancer in 1990-2019: findings from the Global Burden of Disease Study 2019. BMC public health 2022;22:1455.
 - 7. Jiao YS, Gong TT, Wang YL, Wu QJ. Comorbidity and survival among women with ovarian cancer: evidence from prospective studies. Scientific reports 2015;5:11720.
 - 8. Lee L, Cheung WY, Atkinson E, Krzyzanowska MK. Impact of comorbidity on chemotherapy use and outcomes in solid tumors: a systematic review. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2011;29:106-17.
 - 9. Bush WS, Oetjens MT, Crawford DC. Unravelling the human genome–phenome relationship using phenome-wide association studies. Nature Reviews Genetics 2016;17:129-45
 - 10. Davies NM, Holmes MV, Davey Smith G. Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. BMJ 2018;362:k601.
 - 11. Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, Downey P, Elliott P, Green J, Landray M, Liu B, Matthews P, et al. UK Biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLOS Medicine 2015;12:e1001779.
 - 12. Wei WQ, Bastarache LA, Carroll RJ, Marlo JE, Osterman TJ, Gamazon ER, Cox NJ, Roden DM, Denny JC. Evaluating phecodes, clinical classification software, and ICD-9-CM codes for phenome-wide association studies in the electronic health record. PLoS One 2017;12:e0175508.
 - 13. King C, Mulugeta A, Nabi F, Walton R, Zhou A, Hyppönen E. Mendelian randomization case-control PheWAS in UK Biobank shows evidence of causality for smoking intensity in 28 distinct clinical conditions. EClinicalMedicine 2020;26:100488.
 - 14. Verma A, Bradford Y, Dudek S, Lucas AM, Verma SS, Pendergrass SA, Ritchie MD. A simulation study investigating power estimates in phenome-wide association studies. BMC bioinformatics 2018;19:120.
- 15. Phelan CM, Kuchenbaecker KB, Tyrer JP, Kar SP, Lawrenson K, Winham SJ,
 Dennis J, Pirie A, Riggan MJ, Chornokur G, Earp MA, Lyra PC, Jr., et al. Identification of 12
 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nat Genet
 2017;49:680-91.

16. Song H, Ramus SJ, Tyrer J, Bolton KL, Gentry-Maharaj A, Wozniak E, Anton-Culver H, Chang-Claude J, Cramer DW, DiCioccio R, Dörk T, Goode EL, et al. A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. Nat Genet 2009;41:996-1000.

- 17. Goode EL, Chenevix-Trench G, Song H, Ramus SJ, Notaridou M, Lawrenson K, Widschwendter M, Vierkant RA, Larson MC, Kjaer SK, Birrer MJ, Berchuck A, et al. A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nat Genet 2010;42:874-9.
- 18. Bolton KL, Tyrer J, Song H, Ramus SJ, Notaridou M, Jones C, Sher T, Gentry-Maharaj A, Wozniak E, Tsai YY, Weidhaas J, Paik D, et al. Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nat Genet 2010;42:880-4.
- 19. Rafnar T, Gudbjartsson DF, Sulem P, Jonasdottir A, Sigurdsson A, Jonasdottir A, Besenbacher S, Lundin P, Stacey SN, Gudmundsson J, Magnusson OT, le Roux L, et al. Mutations in BRIP1 confer high risk of ovarian cancer. Nat Genet 2011;43:1104-7.
- 20. Couch FJ, Wang X, McGuffog L, Lee A, Olswold C, Kuchenbaecker KB, Soucy P, Fredericksen Z, Barrowdale D, Dennis J, Gaudet MM, Dicks E, et al. Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. PLoS genetics 2013;9:e1003212.
- 21. Pharoah PD, Tsai YY, Ramus SJ, Phelan CM, Goode EL, Lawrenson K, Buckley M, Fridley BL, Tyrer JP, Shen H, Weber R, Karevan R, et al. GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nat Genet 2013;45:362-70, 70e1-2.
- 22. Kuchenbaecker KB, Ramus SJ, Tyrer J, Lee A, Shen HC, Beesley J, Lawrenson K, McGuffog L, Healey S, Lee JM, Spindler TJ, Lin YG, et al. Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nat Genet 2015;47:164-71.
- 23. Kelemen LE, Lawrenson K, Tyrer J, Li Q, Lee JM, Seo JH, Phelan CM, Beesley J, Chen X, Spindler TJ, Aben KK, Anton-Culver H, et al. Genome-wide significant risk associations for mucinous ovarian carcinoma. Nat Genet 2015;47:888-97.
- 24. Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, Motyer A, Vukcevic D, Delaneau O, O'Connell J, Cortes A, Welsh S, et al. The UK Biobank resource with deep phenotyping and genomic data. Nature 2018;562:203-09.
- 25. Carroll RJ, Bastarache L, Denny JC. R PheWAS: data analysis and plotting tools for phenome-wide association studies in the R environment. Bioinformatics 2014;30:2375-76.
- 26. Bowden J, Del Greco MF, Minelli C, Davey Smith G, Sheehan N, Thompson J. A framework for the investigation of pleiotropy in two-sample summary data Mendelian randomization. Stat Med 2017;36:1783-802.
- 27. Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent estimation in mendelian randomization with some invalid instruments using a weighted median estimator. Genet Epidemiol 2016;40:304-14.
- 28. Hartwig FP, Davey Smith G, Bowden J. Robust inference in summary data Mendelian randomization via the zero modal pleiotropy assumption. Int J Epidemiol 2017;46:1985-98.
- 29. Verbanck M, Chen CY, Neale B, Do R. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. Nat Genet 2018;50:693-98.
- 30. Bowden J, Del Greco MF, Minelli C, Davey Smith G, Sheehan NA, Thompson JR. Assessing the suitability of summary data for two-sample Mendelian randomization analyses using MR-Egger regression: the role of the I2 statistic. Int J Epidemiol 2016;45:1961-74.

31. Foley CN, Staley JR, Breen PG, Sun BB, Kirk PDW, Burgess S, Howson JMM. A fast and efficient colocalization algorithm for identifying shared genetic risk factors across multiple traits. Nature communications 2021;12:764.

- 32. Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ. Second-generation PLINK: rising to the challenge of larger and richer datasets. Gigascience 2015;4:7.
- 33. Parsons SL, Lang MW, Steele RJC. Malignant ascites: a 2-year review from a teaching hospital. European Journal of Surgical Oncology (EJSO) 1996;22:237-39.
- 34. Ayantunde AA, Parsons SL. Pattern and prognostic factors in patients with malignant ascites: a retrospective study. Annals of Oncology 2007;18:945-49.
- 35. Kipps E, Tan DS, Kaye SB. Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research. Nat Rev Cancer 2013;13:273-82.
- 36. Ahmed N, Stenvers KL. Getting to know ovarian cancer ascites: opportunities for targeted therapy-based translational research. Front Oncol 2013;3:256.
- 37. Porcel JM, Diaz JP, Chi DS. Clinical implications of pleural effusions in ovarian cancer. Respirology 2012;17:1060-7.
- 38. Xu M, Zhang W, Gao C, Zhou Y, Xie Y. Postoperative pulmonary complications and outcomes in cytoreductive surgery for ovarian cancer: a propensity-matched analysis. BMC anesthesiology 2022;22:120.
- 39. Buckingham EM, Klingelhutz AJ. The role of telomeres in the ageing of human skin. Experimental Dermatology 2011;20:297-302.
- 40. Chen B, Yan Y, Wang H, Xu J. Association between genetically determined telomere length and health-related outcomes: A systematic review and meta-analysis of Mendelian randomization studies. Aging Cell 2023;22:e13874.
- 41. Pomel C, Jeyarajah A, Oram D, Shepherd J, Milliken D, Dauplat J, Reynolds K. Cytoreductive surgery in ovarian cancer. Cancer Imaging 2007;7:210-5.
- 42. Cubillos-Ruiz Juan R, Silberman Pedro C, Rutkowski Melanie R, Chopra S, Perales-Puchalt A, Song M, Zhang S, Bettigole Sarah E, Gupta D, Holcomb K, Ellenson Lora H, Caputo T, et al. ER Stress Sensor XBP1 Controls Anti-tumor Immunity by Disrupting Dendritic Cell Homeostasis. Cell 2015;161:1527-38.
- 43. Mortlock S, Corona RI, Kho PF, Pharoah P, Seo JH, Freedman ML, Gayther SA, Siedhoff MT, Rogers PAW, Leuchter R, Walsh CS, Cass I, et al. A multi-level investigation of the genetic relationship between endometriosis and ovarian cancer histotypes. Cell Rep Med 2022;3:100542.
- 44. Gallagher CS, Mäkinen N, Harris HR, Rahmioglu N, Uimari O, Cook JP, Shigesi N, Ferreira T, Velez-Edwards DR, Edwards TL, Mortlock S, Ruhioglu Z, et al. Genome-wide association and epidemiological analyses reveal common genetic origins between uterine leiomyomata and endometriosis. Nature communications 2019;10:4857.
- 45. Schunkert H, König IR, Kathiresan S, Reilly MP, Assimes TL, Holm H, Preuss M, Stewart AF, Barbalic M, Gieger C, Absher D, Aherrahrou Z, et al. Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet 2011;43:333-8.
- 46. Lindström S, Brody JA, Turman C, Germain M, Bartz TM, Smith EN, Chen MH, Puurunen M, Chasman D, Hassler J, Pankratz N, Basu S, et al. A large-scale exome array analysis of venous thromboembolism. Genet Epidemiol 2019;43:449-57.
- 47. Klarin D, Busenkell E, Judy R, Lynch J, Levin M, Haessler J, Aragam K, Chaffin M, Haas M, Lindström S, Assimes TL, Huang J, et al. Genome-wide association analysis of venous thromboembolism identifies new risk loci and genetic overlap with arterial vascular disease. Nat Genet 2019;51:1574-79.
 - 48. Shah S, Henry A, Roselli C, Lin H, Sveinbjörnsson G, Fatemifar G, Hedman Å K, Wilk JB, Morley MP, Chaffin MD, Helgadottir A, Verweij N, et al. Genome-wide

association and Mendelian randomisation analysis provide insights into the pathogenesis of heart failure. Nature communications 2020;11:163.

- 49. Sakaue S, Kanai M, Tanigawa Y, Karjalainen J, Kurki M, Koshiba S, Narita A, Konuma T, Yamamoto K, Akiyama M, Ishigaki K, Suzuki A, et al. A cross-population atlas of genetic associations for 220 human phenotypes. Nat Genet 2021;53:1415-24.
- 50. Klarin D, Damrauer SM, Cho K, Sun YV, Teslovich TM, Honerlaw J, Gagnon DR, DuVall SL, Li J, Peloso GM, Chaffin M, Small AM, et al. Genetics of blood lipids among ~300,000 multi-ethnic participants of the Million Veteran Program. Nat Genet 2018;50:1514-23.
- 51. Sinnott-Armstrong N, Tanigawa Y, Amar D, Mars N, Benner C, Aguirre M, Venkataraman GR, Wainberg M, Ollila HM, Kiiskinen T, Havulinna AS, Pirruccello JP, et al. Genetics of 35 blood and urine biomarkers in the UK Biobank. Nat Genet 2021;53:185-94.
- 52. Dev S, Babitt JL. Overview of iron metabolism in health and disease. Hemodialysis international. International Symposium on Home Hemodialysis 2017;21 Suppl 1:S6-s20.
- 53. Rafnar T, Gunnarsson B, Stefansson OA, Sulem P, Ingason A, Frigge ML, Stefansdottir L, Sigurdsson JK, Tragante V, Steinthorsdottir V, Styrkarsdottir U, Stacey SN, et al. Variants associating with uterine leiomyoma highlight genetic background shared by various cancers and hormone-related traits. Nature communications 2018;9:3636.
- 54. Schumacher FR, Al Olama AA, Berndt SI, Benlloch S, Ahmed M, Saunders EJ, Dadaev T, Leongamornlert D, Anokian E, Cieza-Borrella C, Goh C, Brook MN, et al. Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. Nat Genet 2018;50:928-36.
- 55. Pendergrass SA, Brown-Gentry K, Dudek SM, Torstenson ES, Ambite JL, Avery CL, Buyske S, Cai C, Fesinmeyer MD, Haiman C, Heiss G, Hindorff LA, et al. The use of phenome-wide association studies (PheWAS) for exploration of novel genotype-phenotype relationships and pleiotropy discovery. Genet Epidemiol 2011;35:410-22.
- 56. Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. Int J Epidemiol 2015;44:512-25.
- 57. Fry A, Littlejohns TJ, Sudlow C, Doherty N, Adamska L, Sprosen T, Collins R, Allen NE. Comparison of sociodemographic and health-related characteristics of UK Biobank participants with those of the general population. Am J Epidemiol 2017;186:1026-34
- 58. Gkatzionis A, Burgess S. Contextualizing selection bias in Mendelian randomization: how bad is it likely to be? Int J Epidemiol 2019;48:691-701.

Figure legends Figure 1. Manhattan plot showing the phenome-wide association of genetic risk scores of overall (Panel A) and subtypes (Panel B) of ovarian cancer with wide ranges of diseases. Panel C summaries the association of the top 15 signals identified at FDR threshold (p =0.0005) in Panel A or Panel B across the different genetic risk scores. The association for the first three diseases (in blue) is a validation of the genetic risk scores. Green highlights indicate association that passed the FDR threshold. Figure 2. Mendelian randomisation causal estimates between ovarian cancer subtypes and selected diseases outcomes. Estimates were from Inverse variance weighted methods. #SNPs are number of genetic variants included in the analyses. Figure 3. Phenome-wide association findings of ovarian cancer risk-increasing variants, with the Manhattan plot showing selected variants associations across all the diseases outcomes (with the yaxis showing the level of significance in -log₁₀ scale), and the forest plot showing the selected variant – disease associations estimate among women and men. **Figure 4.** Colocalisation analysis of ovarian cancer with dermatological condition at the *TERT* locus. Panel A. Stacked regional association plots of ovarian cancer and seborrheic keratosis. Panel B. Portions of the Posterior probability for full colocalisation (PPFC) explained by each genetic variant at the TERT locus. The r^2 colour legends reflect the r^2 of each variant with respect to the lead variant.

549

550

551

552

553

554

555

556

557

558

559

560

561

562

563

564

565


566

Table 1. Prevalence of ovarian cancer by population characteristics

Tables


		All, n (%)	Ovarian cancer,	
			n(%)	p
All		181,203	1,863 (1.3)	
Age (in years)	39–49	40,116 (22.2)	231 (0.6)	1.1 x 10 ⁻⁵¹
8. () ,	50–59	62,041 (34.2)	556 (0.9)	
	60–73	79,046 (43.6)	1,076 (1.4)	
Education	None	31,059 (17.1)	421 (1.4)	0.06
2000000000	NVQ/CSE/A-levels	83,890 (46.3)	819 (1.0)	0.00
	Degree/professional	64,785 (35.8)	607 (0.9)	
	Missing	1,469 (0.8)	16 (1.1)	
BMI (kg/m2)	< 18.5	1,324 (0.7)	10 (0.8)	0.005
(8)	18.5 - <25	70,988 (39.2)	643 (0.9)	
	25 - <30	66,596 (36.8)	713 (1.1)	
	≥ 30	41,746 (23.0)	489 (1.2)	
	Missing	549 (0.3)	9 (1.5)	
Alcohol		7,000 (4.2)	100 (1.4)	
consumption	Never	7,808 (4.3)	109 (1.4)	0.03
1	Previous	6,526 (3.6)	64 (1.0)	
	Current	166,747 (92.0)	1,690 (1.0)	
	Missing	122 (0.1)	0 (0.0)	
General health	Excellent	31,630 (17.5)	286 (0.9)	1.0×10^{-16}
	Good	109,012 (60.2)	1,041 (1.0)	
	Fair	33,519 (18.5)	405 (1.2)	
	Poor	6,431 (3.5)	112 (1.7)	
	Missing	611 (0.3)	19 (3.1)	


p is p-value generated from likelihood ratio test in logistic models adjusted for age, birth location and assessment centers. BMI: body mass index.




			OC	Serous OC	Endometrioid OC	Clear cell OC	Mucinous OC
Disease outcome (Phecode)	Cases,n	Controls,n	Р	Р	Р	Р	Р
Cancer of other female genital organs (184)	2388	122255	4.4E-07	5.2E-05	1.2E-04	2.3E-05	0.04
Malignant neoplasm of ovary and other uterine adnexa (184.1)	2091	122255	2.2E-07	1.7E-04	5.8E-05	3.4E-05	0.05
Malignant neoplasm of ovary (184.11)	2072	122255	1.0E-06	4.8E-04	1.1E-04	4.3E-05	0.04
Secondary malignant neoplasm of digestive systems (198.3)	1084	122255	2.0E-06	4.1E-05	0.009	0.003	0.69
Ascites (572)	845	104686	3.2E-04	0.01	0.007	0.04	0.66
Chronic airway obstruction (496)	5229	146930	1.0E-04	0.002	0.01	0.09	0.86
Abnormal findings examination of lungs (514)	1193	146930	6.9E-05	1.2E-04	0.12	0.07	0.68
Postoperative infection (80)	2153	164159	0.002	0.005	0.005	2.3E-04	0.78
Gram negative septicemia (38.1)	385	164159	0.007	0.007	0.52	3.2E-05	0.81
Benign neoplasm of uterus (218)	9234	122255	0.002	4.4E-04	0.60	1.9E-08	0.72
Uterine leiomyoma (218.1)	9008	122255	0.007	0.001	0.66	3.7E-08	0.93
Disorders of menstruation* (626)	15578	116934	0.03	0.002	0.22	1.5E-04	0.30
Ovarian cyst (628)	4147	116934	6.0E-05	8.9E-04	0.39	1.0E-05	0.92
Lipoma (214)	2636	122255	3.9E-04	0.02	0.04	0.12	0.03
Lipoma of skin and subcutaneous tissue (214.1)	2171	122255	3.7E-05	0.008	0.09	0.08	0.03

	#SNPs		OR (95% CI)
Secondary malignant neoplasm of digestive system	15		
Ovarian cancer (OC)	31		1.64 (1.33, 2.0
Serous OC	20		1.34 (1.17, 1.5
Endometrioid OC	5		1.82 (1.18, 2.8
Clear Cell OC	5	I —	1.55 (1.16, 2.0
Mucinous OC	8	- ₱-	1.02 (0.82, 1.2
Ascites		- 1	
Overien cencer (OC)	31		1.48 (1.17, 1.8
Serous OC	20	I- -	1.24 (1.07, 1.4
Endometrioid OC Clear Cell OC	5	I——	1.99 (1.06, 3.7
Clear Cell OC	5	_ -	1.40 (1.01, 1.9
Mucinous OC	8	+-	1.04 (0.85, 1.2
Chronic airway obstruction		- 1	
Overien cencer (OC)	31	-	1.17 (1.07, 1.2
Serous OC	20	L=	1.10 (1.03, 1.1
Endometrioid OC	5		1.29 (1.04, 1.5
Dear Cell OC	5	La.	1.12 (0.97, 1.2
Mucinous OC	š	1-	1.01 (0.94, 1.0
		Ī	
Abnormal findings examination of lungs Overien cancer (OC)	31	l	1.51 (1.22, 1.8
Serous OC	20	1	1.28 (1.09, 1.5
Serous OC Endometrioid OC	20 5	 -	1.20 (1.09, 1.5
			1.43 (0.85, 2.4
Clear Cell OC Mucinous OC	5	_ -	1.29 (0.95, 1.7
Woonbus OC	8	+	0.98 (0.84, 1.1
Ovarian cyst		ı	
Ovarian cancer (OC)	31	- ■-	1.23 (1.04, 1.4
Serous OC	20	 - -	1.11 (0.99, 1.2
Endometrioid OC	5		1.11 (0.79, 1.5
Clear Cell OC	5	I	1.39 (1.08, 1.7
Mucinous OC	8		0.99 (0.83, 1.1
Lipoma		1	
Ovarian cancer (OC)	31	L	1.24 (1.02, 1.5
Serous OC	20		1.13 (0.98, 1.3
Serous OC Endometrioid OC	20	T	1.13 (0.98, 1.3
Endometroid OC Clear Cell OC	5	T-	1.39 (0.69, 2.1
Marineus OC	8	T.	1.16 (0.90, 1.4 1.14 (1.02, 1.2
		I-	1.14 (1.02, 1.2
Lipoma of skin and subcutaneous tissue		_ I	
Ovarian cancer (OC)	31	- - -	1.31 (1.06, 1.6
Serous OC	20	H=-	1.16 (1.00, 1.3
Endometrioid OC	5	+-	1.34 (0.84, 2.1
Clear Cell OC	5	⊢= −	1.20 (0.98, 1.4
Mucinous OC	8		1.15 (1.03, 1.2
Postoperative infection			
Overien cencer (OC)	31	I- - -	1.28 (1.10, 1.4
Servis OC	20	La-T	1.15 (1.02, 1.2
Enformatrioid OC	5		1.61 (0.93, 2.7
Clear Cell OC	5		1.47 (1.05, 2.0
		I——	
Mucinous OC	8	+	1.00 (0.89, 1.1
Gram negative septicemia		- 1	
Ovarian cancer (OC)	31	I—•	1.55 (1.06, 2.2
Serous OC	20	H-	1.29 (0.98, 1.6
Endometrioid OC	5		1.26 (0.60, 2.6
Clear Cell OC	5	· · · · · · · · ·	2.74 (1.69, 4.4
Mucinous OC	8		1.05 (0.80, 1.3
		1	
Benign neoplasm of uterus Ovarian carcer (OC)	31	1	1.13 (0.95, 1.3
Overien cancer (OC) Serous OC	20	1	1.13 (0.95, 1.2
Endometrioid OC	5		1.04 (0.66, 1.6
Clear Cell OC	5		1.04 (0.66, 1.6
	8	1	
Mucinous OC	۰	Ŧ	1.01 (0.93, 1.1
Uterine leiomyoma		1	
Ovarian cancer (OC)	31	 = -	1.11 (0.94, 1.3
Serous OC	20	1 -	1.09 (0.96, 1.2
Endometrioid OC	5		1.03 (0.66, 1.6
Clear Cell OC	5	[1.34 (1.08, 1.6
Mucinous OC	8	ļ	1.00 (0.92, 1.0
		Ī	
	31	L	400.00.5
Disorders of menstruation		E	1.06 (0.97, 1.1 1.06 (0.99, 1.1
Ovarian cancer (OC)		-	1.06 (0.99, 1.1
Ovarian cancer (OC) Serous OC	20		
Overien cancer (OC) Serous OC Enformation OC	5	 ■ -	1.08 (0.91, 1.2
Ovarian cancer (OC) Serous OC Endometrioid OC Clear Cell OC	5 5	1=	1.17 (1.05, 1.3
Disorders of menstruation Ovarian cancer (OC) Senous OC Endometricid OC Clear Cell OC Mucinous OC	5		1.08 (0.91, 1. 1.17 (1.05, 1. 1.02 (0.96, 1.







Phenome-wide association study of ovarian cancer identifies common comorbidities and reveals shared genetics with complex diseases and biomarkers



181,203 female participants



889 diseases



43 biomarkers and physiological measures




ovarian cancer (OC) genetic variants

Genetic risk score (GRS)

for OC and the subtypes (serous, clear cell, endometrioid, and mucinous OC)

PheWAS validated the association between OC GRS and OC.

GRSs for OC or its subtypes were also associated with 12 other diseases, as well as 24 biomarkers and physiological measures




MR provided robust evidence of association between OC and the following diseases:

(a) Respiratory system

- Chronic airway obstruction
- Abnormal findings examination of the lungs
- Lower forced vital capacity (FVC)

(b) Digestive system

- Ascites
- Secondary malignant neoplasm of the digestive systems



PheWAS and Colocalisation analysis identified shared locus (*TERT,* rs4449583 potential causal variant) between OC and dermatological condition.

